跳轉至內容
Merck
全部照片(1)

Key Documents

D1446

Sigma-Aldrich

右丙亚胺

≥95% (HPLC)

同義詞:

(+)-(S)-4,4′-丙烯二-2,6-哌嗪二酮, ICRF-187, NSC169780, Zinecard, 心氧烷, (S)-(+)-1,2-双(3,5-二氧杂哌嗪-1-基)丙烷

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C11H16N4O4
CAS號碼:
分子量::
268.27
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥95% (HPLC)

形狀

powder

顏色

white to off-white

溶解度

DMSO: >20 mg/mL

起源

Johnson & Johnson

儲存溫度

room temp

SMILES 字串

C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2

InChI

1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1

InChI 密鑰

BMKDZUISNHGIBY-ZETCQYMHSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

Dexrazoxane is a member of bis(2,6-dioxopiperazines), that functions as a topoisomerase 2 catalytic inhibitor. Dexrazoxane is a free radical scavenger. It might protect the heart from doxorubicin-associated damage. Dexrazoxane acts as a cardiopulmonary protectant, while treating Hodgkin′s disease (HD). It functions as a chelating agent, which limits the formation of anthracycline-iron complexes. It is used to synthesize antimalarial drugs.

應用

Dexrazoxane has been used in chromatin remodelling experiments.

生化/生理作用

右雷佐生是抗蒽环类的心脏保护化合物。它通过抑制拓扑异构酶 II 而起作用,而不会引起 DNA 链断裂。右雷佐生是丙亚胺的 + 对映异构体。

特點和優勢

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
Tebbi CK, et al.
Journal of Clinical Oncology, 25(5), 493-500 (2007)
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia
Lipshultz SE, et al.
The New England Journal of Medicine, 351(2), 145-153 (2004)
Topoisomerase IIβ-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane
Lyu YL, et al.
Cancer Research, 67(18), 8839-8846 (2007)
J S Whelan et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 26(2), 407-414 (2014-11-26)
Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response. Patients with resectable osteosarcoma aged ≤40 years were treated
Volume Transitions of Isolated Cell Nuclei Induced by Rapid Temperature Increase
Chan CJ, et al.
Biophysical Journal, 112(6), 1063-1076 (2017)

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務